Vaccines and broadly neutralizing antibodies for HIV-1 prevention
Annual review of immunology, 2020•annualreviews.org
Development of improved approaches for HIV-1 prevention will likely be required for a
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early
phase clinical trials offer renewed promise for immunologic strategies for blocking
acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of
two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1
infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active …
durable end to the global AIDS pandemic. Recent advances in preclinical studies and early
phase clinical trials offer renewed promise for immunologic strategies for blocking
acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of
two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1
infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active …
Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.
Annual Reviews